Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NADK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
NADK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of NADK2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
NAGK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
NAGK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of NAGK sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MKNK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MKNK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MKNK1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MIPEP Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MIPEP Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MIPEP sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MINK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MINK1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MINK1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MVK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MVK Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MVK sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MKNK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MKNK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MKNK2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
METAP2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
METAP2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of METAP2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MGAT5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MGAT5 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MGAT5 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MGAT4A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MGAT4A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MGAT4A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
METAP1D Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
METAP1D Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of METAP1D sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
METAP1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
METAP1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of METAP1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →